License and Collaboration Agreements (Tables)

6 Months Ended

Jun. 30, 2013

Organization Consolidation And Presentation Of Financial Statements [Abstract]

License, Collaboration and Other Revenue

In accordance with our collaboration agreements, we recognized license, collaboration and other revenue as follows (in thousands):

		Three months ended June 30,				Six months ended June 30,
Partner	Drug or Drug Candidate	2013		2012		2013		2012
Bayer Healthcare LLC	BAY41-6551 (Amikacin Inhale)	$	13,111	$	799	$	13,825	$	1,543
Roche	PEGASYS® and MIRCERA®		2,625		1,743		5,250		3,124
Amgen, Inc.	Neulasta®		1,250		1,250		2,535		2,500
Baxter Healthcare	Hemophilia		597		4,369		1,297		5,053
Affymax, Inc.	Omontys®		193		194		370		2,411
Other			1,583		1,876		2,558		3,427
License, collaboration, and other revenue		$	19,359	$	10,231	$	25,835	$	18,058